EMCURE PHARMACEUTICALS
|
The Current P/E Ratio of EMCURE PHARMACEUTICALS is 37.18.
| Share Price | ₹1,997.0 | Aug 10,2026 |
| Market Cap | ₹37,883.1 Cr | |
| Earnings-TTM | ₹1,019.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 37.18x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of EMCURE PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹37,883.1 Cr] as on Aug 10,2026
(/) Earnings [ ₹1,019.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 37.18x ]
Thus, for EMCURE PHARMACEUTICALS , the investors are currently willing to pay 37.18 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of EMCURE PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of EMCURE PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of EMCURE PHARMACEUTICALS
PE Ratio Performance Analysis for EMCURE PHARMACEUTICALS
- EMCURE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 5.97x.
- EMCURE PHARMACEUTICALS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, EMCURE PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 29.84x.
- EMCURE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does EMCURE PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| EMCURE PHARMACEUTICALS | 1,018.97 | 37.18 | 37,883.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 38.49 | 468,530.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 75.10 | 219,675.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.72 | 186,970.0 |
| CIPLA LTD | 3,364.84 | 35.05 | 117,947.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.48 | 96,601.2 |
| MANKIND PHARMA LTD | 2,055.11 | 48.99 | 100,688.0 |
| LUPIN LTD | 5,551.01 | 18.74 | 104,021.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.24 | 111,790.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.51 | 94,707.2 |
| LAURUS LABS LTD | 1,090.76 | 92.43 | 100,822.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs EMCURE PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.74x |
| Max industry PE | 92.43x |
| Median industry PE | 37.18x |
| Average industry PE | 46.45x |
You may also like the below Video Courses